Avalo Therapeutics, Inc. (NASDAQ:AVTX) is one of the top long-term biotechnology stocks to buy. On October 17, Piper Sandler analyst Yasmeen Rahimi reaffirmed her Buy rating on Avalo Therapeutics Inc. (NASDAQ:AVTX), maintaining a price target of $48, which implies a substantial upside potential of 167.86% from the stock’s current trading levels. Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) The buy stance underscores confidence in Avalo’s strategic direction and pipeline p ...